Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib

被引：15

作者：

Bornhäuser, M ^{[1
]}

Pursche, S ^{[1
]}

Bonin, M ^{[1
]}

Freiberg-Richter, J ^{[1
]}

Jenke, A ^{[1
]}

Illmer, T ^{[1
]}

Ehninger, G ^{[1
]}

Schleyer, E ^{[1
]}

机构：

[1] Univ Hosp, Dept Hematol Oncol, Dresden, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期

关键词：

D O I：

10.1200/JCO.2005.05.246

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3855 / 3857

页数：3

共 7 条

[1] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[2] Cyclophosphamide metabolism is affected by azole antifungals [J].

Marr, KA ;

Leisenring, W ;

Crippa, F ;

Slattery, JT ;

Corey, L ;

Boeckh, M ;

McDonald, GB .

BLOOD, 2004, 103 (04) :1557-1559

[3] Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation [J].

McDonald, GB ;

Slattery, JT ;

Bouvier, ME ;

Ren, S ;

Batchelder, AL ;

Kalhorn, TF ;

Schoch, HG ;

Anasetti, C ;

Gooley, T .

BLOOD, 2003, 101 (05) :2043-2048

[4] Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia [J].

O'Brien, SG ;

Meinhardt, P ;

Bond, E ;

Beck, J ;

Peng, B ;

Dutreix, C ;

Mehring, G ;

Milosavljev, S ;

Huber, C ;

Capdeville, R ;

Fischer, T .

BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1855-1859

[5] Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients [J].

Peng, B ;

Hayes, M ;

Resta, D ;

Racine-Poon, A ;

Druker, BJ ;

Talpaz, M ;

Sawyers, CL ;

Rosamilia, M ;

Ford, J ;

Lloyd, P ;

Capdeville, R .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :935-942

[6] Absolute bioavailability of imatinib (Glivec®) orally versus intravenous infusion [J].

Peng, B ;

Dutreix, C ;

Mehring, G ;

Hayes, MJ ;

Ben-Am, M ;

Seiberling, M ;

Pokorny, R ;

Capdeville, R ;

Lloyd, P .

JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (02) :158-162

[7] Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations [J].

Schleyer, E ;

Pursche, S ;

Köhne, CH ;

Schuler, U ;

Renner, U ;

Gschaidmeier, H ;

Freiberg-Richter, J ;

Leopold, T ;

Jenke, A ;

Bonin, M ;

Bergemann, T ;

le Coutre, P ;

Gruner, M ;

Bornhäuser, M ;

Ottmann, OG ;

Ehninger, G .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 799 (01) :23-36

← 1 →